Can Injective Price Reach $7 Next?

Injective price surged nearly 10% following renewed optimism surrounding Canary Capital’s proposed staked INJ ETF boosted investor sentiment. The latest filing provides greater regulatory clarity, institutional custody solutions, and staking mechanisms, strengthening the long-term investment case for the token. 

As institutional interest grows, traders are now evaluating whether INJ price has enough momentum to reclaim the crucial $7 resistance level.

Canary ETF Filing Strengthens the Institutional Narrative

Market sentiment surrounding Injective improved considerably after Canary Capital submitted its latest amendment for the proposed staked INJ ETF. The filing provides one of the most detailed frameworks yet for a staking-based cryptocurrency investment product.

The proposed fund would trade under the ticker INJS while actively staking its INJ holdings to generate network rewards. The structure allows investors to gain exposure to both the token’s price performance and staking income, creating a differentiated investment product compared to traditional spot ETFs.

The filing also introduces institutional-grade custody arrangements through BitGo and adopts a cash-based creation and redemption mechanism. Furthermore, the proposal addresses Injective’s unstaking requirements by maintaining liquid reserves to support investor redemptions. These developments have improved confidence that Injective may become one of the first emerging Layer-1 networks to receive significant institutional attention through regulated investment products.

Growing Institutional Interest Could Become a Major Catalyst

The ETF narrative arrives at a time when institutions are increasingly exploring digital assets beyond Bitcoin and Ethereum. Investors have gradually shifted their attention toward blockchain networks that combine strong fundamentals with real-world utility. Injective’s focus on decentralized finance, derivatives infrastructure, tokenized assets, and cross-chain applications has positioned the network differently from many competing Layer-1 projects.

The proposed ETF could further expand Injective’s visibility among traditional investors by offering regulated exposure to the asset while generating staking yields. This combination of yield generation and price appreciation may become increasingly attractive as institutional participation in crypto markets expands. As a result, many investors now view the ETF filing as a long-term growth catalyst rather than simply a short-term trading narrative.

INJ Price Analysis: Can Bulls Reclaim $7?

INJ token remains in a recovery phase after experiencing a prolonged correction from previous highs. Injective price has successfully defended the $4 support region, which has emerged as a major accumulation zone over recent months. Buyers have repeatedly stepped into this area, preventing further downside and helping establish a stronger base.

The immediate resistance level now sits near $5.20. A breakout above this region could open the path toward $6, where previous selling pressure emerged. Beyond that, the major supply zone between $7 and $7.50 represents the next significant target for bulls. The recent rebound also suggests that Injective token may be attempting to establish a higher low, which often serves as an early indication of a broader trend reversal. However, failure to maintain support above $4 could weaken the bullish structure and expose the token to renewed selling pressure.

Is Injective Preparing for Another Rally?

The latest ETF development has provided Injective with one of its strongest institutional narratives to date. Combined with improving market sentiment and growing ecosystem activity, the filing has strengthened the long-term outlook for the network.

As long as INJ continues holding above its key support zone, buyers may attempt another move toward $5.50 and $6 in the coming weeks. A successful breakout above those levels could eventually allow bulls to challenge the major $7 resistance area. For now, the ETF catalyst has placed Injective back on investors’ watchlists, and the market will closely monitor whether institutional optimism can translate into sustained price momentum.

Story Ends Here

Read the Next News